factory lower price 341031-54-7

Min.Order / FOB Price:Get Latest Price

100 Kilogram	Negotiable

100 Kilogram

Negotiable

Min.Order :100 Kilogram
Purity: 99%
Payment Terms : L/C,D/A,D/P,T/T,Other

Keywords

Sunitinib Malate 341031-54-7 C22H27FN4O2.C4H6O5

Quick Details

Appearance:powder
Application:341031-54-7
PackAge:Depended
ProductionCapacity:300|Kilogram|Month
Storage:Refrigerator
Transportation:by air or by sea

Superiority:

Sunitinib Malate Basic information

Anticancer drug Application

Product Name:	Sunitinib Malate
Synonyms:	SUNITINIB MALATE;N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate;N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidine)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide(2S)-2-hydroxybutanedioatesalt;Sunitinib Malate(Sutent);Butanedioic acid, 2-hydroxy-, (2S)-, coMpd. with N-[2-(diethylaMino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)Methyl]-2,4-diMethyl-1H-pyrrole-3-carboxaMide (1:1);N-(2-(DiethylaMino)ethyl)-5-((Z)-(5-fluoro-1,2-dih;Butanedioic acid, 2-hydroxy-, (2S)-, coMpd. with N-[2-(diethylaMino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)Methyl]-2,4-diMethyl-1H-pyrrole-3-carboxaMide;(Z)-N-(2-(diethylaMino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)Methyl)-2,4-diMethyl-1H-pyrrole-3-carboxaMide (S)-2-hydroxysuccinate
CAS:	341031-54-7
MF:	C22H27FN4O2.C4H6O5
MW:	532.566
EINECS:
Product Categories:	APIs;Heterocycles;Intermediates & Fine Chemicals;Pfizer compounds;Pharmaceuticals;Tyrosine Kinase Inhibitors;SU-11248;Inhibitors
Mol File:	341031-54-7.mol

Sunitinib Malate Chemical Properties

mp	189-191°C
storage temp.	Store at +4°C
CAS DataBase Reference	341031-54-7(CAS DataBase Reference)

Safety Information

Hazard Codes	T
Risk Statements	61-2-48/25
Safety Statements	53-22-36/37

MSDS Information

Sunitinib Malate Usage And Synthesis

Anticancer drug	Sunitinib malate is a kind of novel oral multi-targeted anticancer drugs and belongs to multi-targeted tyrosine kinase inhibitor with its trade name being “suntent”. It was successfully developed by Pfizer Company and has dual anti-tumor effect. Moreover, it is the only therapeutic drug which can go beyond the 2-year survival period of advanced kidney cancer and plays a central role in the field of carcinoma and gastrointestinal stromal tumor therapeutic areas. It entered into market in February 2006 in the United States. This drug was the first anti-cancer drug which was approved by the US FDA and can simultaneously treat two diseases. Sunitinib exerts its therapeutic role through preventing the tumor cells from getting the blood and nutrients needed for growth. Clinical trials have showed that the drug can delay the growth rate of gastrointestinal stromal tumors, and can shrink the size of renal cell tumors. Sunitinib malate is the first novel targeted drug being capable of selectively targets drugs for a variety of new tyrosine kinase receptors. It combine two kinds of anti-tumor mechanisms including both stopping the formation of anti-angiogenic which is responsible for supplying blood to tumor and direct attack of tumor cells. It represents the advent of a new round of targeted therapies, being able to attack the tumor directly without the toxicity of the conventional chemotherapy. The indications of Sunitinib malate are as follows: 1, Patients who failed in the treatment with matinib mesylate or of intolerant gastrointestinal stromal tumors (GIST). 2, inoperable advanced renal cell carcinoma (RCC). 3, advanced pancreatic endocrine tumors. The above information is edited by the Chemicalbook of Dai Xiongfeng.
Application	Anti-cancer drugs
Chemical Properties	Yellow Solid
Usage	Sunitinib Malate (Sutent, SU11248) is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.
Usage	Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit
Usage	A multi-kinase inhibitor targeting several receptor tyrosine kinases (RTK). Antineoplastic.
Biological Activity	Potent, ATP-competitive VEGFR, PDGFR β and KIT inhibitor (K i values are 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFR β and KIT respectively). Also inhibits cellular receptor phosphorylation of FLT3, RET and CSF-1R. Exhibits antiangiogenic and antitumor activity in multiple xenograft models.

Service we provide:

1. Mixed container, we can mix different items in one container.

2. Quality control, before shipment, free sample for test. after shipment, keep sample for 3 years

3. Prompt shipment with professional documents

4. Packing as your request, with photo before shipment

Details:

Exhibition in shanghai

We have clients throughout the world：

Professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet your desire.

Our Laboratoy

We have our own independent lab test center：

This makes sure that our technology support is reliable and authoritative.All of self-owned fine chemicals are manufactured strictly in accordance with international standard.,and also has scientific cooperation with local colleges and institutes.